SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Rakovina Therapeutics and Celvion Complete AI Analysis of Cancer Indications

The companies said the analysis identified priority cancer indications for Rakovina’s brain-penetrant ATR inhibitor program, using the EMphora platform to inform further research.

SquawkNews Desk

Related stories

Universal Music Group Reports Third-Quarter and Nine-Month Results M impact | EQUITY | Oct 29, 2026, 04:54 PM UTC RBC Says ServiceNow Investors Seek Proof of AI Monetization After Q3 Results ServiceNow's Q3 results beat guidance but fell short of an unspecified measure, according to the report. M impact | EQUITY | Oct 29, 2026, 04:48 PM UTC Amplifon Reports Q3 Adjusted Net Profit of €26.6 Million M impact | EQUITY | Oct 29, 2026, 04:47 PM UTC UMG Q3 Recorded Music Subscription Revenue Grew 19.2% Revenue growth was 9.5% excluding Downtown. M impact | EQUITY | Oct 29, 2026, 04:47 PM UTC AXA Reports 5% Rise in Nine-Month Life and Health Premiums AXA reported a 5% increase in premiums over nine months, driven by life and health insurance. M impact | EQUITY | Oct 29, 2026, 04:47 PM UTC AXA Reports 9-Month Gross Written Premiums and Other Revenues of €93.0 Billion M impact | EQUITY | Oct 29, 2026, 04:46 PM UTC